BR0016672A - Constructo de vacina de ácido nucleico, composição de vacina, uso de um constructo de vacina de ácido nucleico, e, método de vacinação de um mamìfero contra tumores - Google Patents
Constructo de vacina de ácido nucleico, composição de vacina, uso de um constructo de vacina de ácido nucleico, e, método de vacinação de um mamìfero contra tumoresInfo
- Publication number
- BR0016672A BR0016672A BR0016672-3A BR0016672A BR0016672A BR 0016672 A BR0016672 A BR 0016672A BR 0016672 A BR0016672 A BR 0016672A BR 0016672 A BR0016672 A BR 0016672A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- acid vaccine
- vaccine construct
- construct
- vaccination
- Prior art date
Links
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract 5
- 229940023146 nucleic acid vaccine Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 230000013595 glycosylation Effects 0.000 abstract 3
- 238000006206 glycosylation reaction Methods 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
"CONSTRUCTO DE VACINA DE áCIDO NUCLEICO, COMPOSIçãO DE VACINA, USO DE UM CONSTRUCTO DE VACINA DE áCIDO NUCLEICO, E, MéTODO DE VACINAçãO DE UM MAMìFERO CONTRA TUMORES". Um constructo de vacina de ácido nucleico compreendendo um polinucleotídeo isolado que codifica um polipeptídeo compreendendo pelo menos cinco resíduos de aminoácido consecutivos do monómero VNTR de Mucl no qual um ou mais dos citados aminoácidos é um sítio de glicosilação, caracterizado pelo fato de que quando o polinucleotídeo isolado é expressado em uma célula de mamífero, a glicosilação do polipeptídeo resultante é alterada ou prevenida em pelo menos um dos citados sítios de glicosilação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930359.6A GB9930359D0 (en) | 1999-12-22 | 1999-12-22 | Novel polypeptides |
| PCT/GB2000/004906 WO2001046228A2 (en) | 1999-12-22 | 2000-12-20 | Nucleic acid vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0016672A true BR0016672A (pt) | 2002-10-08 |
Family
ID=10866857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0016672-3A BR0016672A (pt) | 1999-12-22 | 2000-12-20 | Constructo de vacina de ácido nucleico, composição de vacina, uso de um constructo de vacina de ácido nucleico, e, método de vacinação de um mamìfero contra tumores |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20030133909A1 (pt) |
| EP (1) | EP1240317B1 (pt) |
| JP (1) | JP2003517845A (pt) |
| KR (1) | KR20020073149A (pt) |
| CN (1) | CN1434862A (pt) |
| AT (1) | ATE355365T1 (pt) |
| AU (1) | AU2204901A (pt) |
| BR (1) | BR0016672A (pt) |
| CA (1) | CA2395208A1 (pt) |
| CZ (1) | CZ20022192A3 (pt) |
| DE (1) | DE60033690T2 (pt) |
| ES (1) | ES2282156T3 (pt) |
| GB (1) | GB9930359D0 (pt) |
| HU (1) | HUP0203848A3 (pt) |
| IL (1) | IL150285A0 (pt) |
| MX (1) | MXPA02006313A (pt) |
| NO (1) | NO20023010L (pt) |
| NZ (1) | NZ519732A (pt) |
| PL (1) | PL356697A1 (pt) |
| WO (1) | WO2001046228A2 (pt) |
| ZA (1) | ZA200204987B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0212046D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| RU2718663C2 (ru) | 2016-01-19 | 2020-04-13 | Пфайзер Инк. | Противораковые вакцины |
| CN106086050B (zh) * | 2016-06-28 | 2020-01-07 | 中国人民解放军第二军医大学 | 携带muc1肿瘤抗原表位pdtrp的嵌合型病毒样颗粒及在胰腺癌中的应用 |
| AU2018326805B2 (en) | 2017-09-01 | 2023-11-30 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DE19516673A1 (de) * | 1995-04-28 | 1996-10-31 | Gabriele Dr Pecher | Vakzine gegen Tumorerkrankungen |
| AUPN568095A0 (en) * | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
| EP0923605A4 (en) * | 1996-03-20 | 2003-01-02 | Sloan Kettering Inst Cancer | CONJUGATE VACCINES CONTAINING MUCIN PEPTIDE |
| US5744177A (en) * | 1996-06-11 | 1998-04-28 | Lin; Rong-Teng | Injection molding assembly |
-
1999
- 1999-12-22 GB GBGB9930359.6A patent/GB9930359D0/en not_active Ceased
-
2000
- 2000-12-20 IL IL15028500A patent/IL150285A0/xx unknown
- 2000-12-20 MX MXPA02006313A patent/MXPA02006313A/es unknown
- 2000-12-20 ES ES00985646T patent/ES2282156T3/es not_active Expired - Lifetime
- 2000-12-20 CA CA002395208A patent/CA2395208A1/en not_active Abandoned
- 2000-12-20 DE DE60033690T patent/DE60033690T2/de not_active Expired - Lifetime
- 2000-12-20 CN CN00819076A patent/CN1434862A/zh active Pending
- 2000-12-20 AU AU22049/01A patent/AU2204901A/en not_active Abandoned
- 2000-12-20 BR BR0016672-3A patent/BR0016672A/pt not_active IP Right Cessation
- 2000-12-20 PL PL00356697A patent/PL356697A1/xx not_active Application Discontinuation
- 2000-12-20 EP EP00985646A patent/EP1240317B1/en not_active Expired - Lifetime
- 2000-12-20 HU HU0203848A patent/HUP0203848A3/hu unknown
- 2000-12-20 CZ CZ20022192A patent/CZ20022192A3/cs unknown
- 2000-12-20 KR KR1020027008063A patent/KR20020073149A/ko not_active Application Discontinuation
- 2000-12-20 JP JP2001547137A patent/JP2003517845A/ja active Pending
- 2000-12-20 AT AT00985646T patent/ATE355365T1/de not_active IP Right Cessation
- 2000-12-20 US US10/168,873 patent/US20030133909A1/en not_active Abandoned
- 2000-12-20 WO PCT/GB2000/004906 patent/WO2001046228A2/en active IP Right Grant
- 2000-12-20 NZ NZ519732A patent/NZ519732A/en unknown
-
2002
- 2002-06-20 ZA ZA200204987A patent/ZA200204987B/en unknown
- 2002-06-21 NO NO20023010A patent/NO20023010L/no not_active Application Discontinuation
-
2006
- 2006-11-02 US US11/555,793 patent/US20070269451A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2282156T3 (es) | 2007-10-16 |
| US20030133909A1 (en) | 2003-07-17 |
| DE60033690D1 (de) | 2007-04-12 |
| DE60033690T2 (de) | 2007-11-08 |
| CN1434862A (zh) | 2003-08-06 |
| AU2204901A (en) | 2001-07-03 |
| IL150285A0 (en) | 2002-12-01 |
| PL356697A1 (en) | 2004-06-28 |
| ATE355365T1 (de) | 2006-03-15 |
| NO20023010D0 (no) | 2002-06-21 |
| WO2001046228A2 (en) | 2001-06-28 |
| NZ519732A (en) | 2004-03-26 |
| CZ20022192A3 (cs) | 2002-11-13 |
| CA2395208A1 (en) | 2001-06-28 |
| MXPA02006313A (es) | 2002-11-29 |
| WO2001046228A3 (en) | 2002-01-17 |
| GB9930359D0 (en) | 2000-02-09 |
| EP1240317B1 (en) | 2007-02-28 |
| US20070269451A1 (en) | 2007-11-22 |
| NO20023010L (no) | 2002-08-06 |
| KR20020073149A (ko) | 2002-09-19 |
| ZA200204987B (en) | 2003-09-22 |
| JP2003517845A (ja) | 2003-06-03 |
| HUP0203848A3 (en) | 2004-07-28 |
| HUP0203848A2 (hu) | 2003-03-28 |
| EP1240317A2 (en) | 2002-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2660355A1 (en) | Polynucleotide vaccine formulation against pathologies of the horse | |
| BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
| BR9605153B1 (pt) | vacina de combinação, e, kit de vacinação. | |
| NO2007008I2 (no) | Analoger av humant erytropoietin,DNA-sekvenser somkoder for disse, eukaryot vertscelle transfektert med DNA-sekvensene, preparat som omfatter analoge ne, anvendelse av analogene til økning av hematokritt, og fremgangsmåte for fremstilling av analogene. | |
| GR3022850T3 (en) | Synthetic DNA derived recombinant HIV-1 antigens | |
| BR9206559A (pt) | Composição para introdução de complexos de ácido nucléico em células eucarióticas superiores | |
| CA2173975A1 (en) | Recombinant adenoviral vector and methods of use | |
| ATE236249T1 (de) | Tfn-bindende proteine | |
| ES555124A0 (es) | Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas | |
| BR0016672A (pt) | Constructo de vacina de ácido nucleico, composição de vacina, uso de um constructo de vacina de ácido nucleico, e, método de vacinação de um mamìfero contra tumores | |
| CY1105604T1 (el) | Μεθοδος ενισχυσης ανοσων απαντησεων στο εμβολιο κατα του ιου του απλου ερπητα | |
| BR9707785A (pt) | Parapoxvírus que contém dna estrangeiro preparação dos mesmos e uso dos mesmos em vacinas | |
| DK0506778T3 (da) | Substituerede 4-phenyl-4-piperidincarboxamider med både lokal anæstetisk og analgetisk virkning samt fremgangsmåder til deres fremstilling | |
| DE69836520D1 (de) | Clostridium perfringens Impfstoff | |
| EP0256677A3 (en) | Pseudorabies virus recombinants and their use in the production of proteins | |
| BR9912626A (pt) | Mutante do herpesvìrus equino, sequência de ácido nucleico, molécula de dna recombinante, célula hospedeira, vacina, e, processos para a preparação de um mutante de ehv e para atenuar geneticamente o ehv | |
| DK0845034T3 (da) | Peptid med pronociceptive egenskaber | |
| SE9602822D0 (sv) | New receptor | |
| ATE341339T1 (de) | Zusammensetzungen von rekombinanten papillomavirus vakzinen | |
| DK312787A (da) | Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne | |
| ES2080060T3 (es) | Proteinas que tienen actividad de union a interferon-gamma. | |
| BR9909173A (pt) | ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus | |
| CA2148369A1 (en) | Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof | |
| HUP9904201A1 (hu) | Génterápiában használható, egy exogén nukleinsavat genomjában beépítve tartalmazó rekombináns vírus és egy nem virális és nem plazmid transzfektáló szer kombinációját tartalmazó transzfektáló készítmény | |
| BR9909655A (pt) | Aperfeiçoamentos em ou com relação ao metabolismo de ácido graxo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |